SCHEMBL16206147

SCHEMBL16206147

Cc1cccc(-n2nnn(C)c2=O)c1COc1cccc(-c2ccc(Cl)cc2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 1/20 0.40
EGLN1 Q9GZT9 1/20 0.37
FFAR1 O14842 1/20 0.36
MEN1 O00255 1/20 0.36
TSHR P16473 1/20 0.36
KMT2A Q03164 1/20 0.36
POLB P06746 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
NR1H4 Q96RI1 1/20 0.35
SMPD1 P17405 1/20 0.35
PTGER4 P35408 1/20 0.35
MAOB P27338 1/20 0.35
CYP3A4 P08684 1/20 0.35
MAPT P10636 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
RXRA P19793 1/20 0.34
RXRB P28702 1/20 0.34
NR4A2 P43354 1/20 0.34
SOD1 P00441 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16205998 0.93 SLC22A12 (0.40) SLC22A12EGLN1FFAR1MEN1KMT2A
SCHEMBL16609264 0.92 NR1H4 (0.39) MEN1TSHRKMT2APOLBRXFP1
SCHEMBL16206150 0.92 SLC22A12 (0.41) SLC22A12FFAR1TSHRNR1H4PTGER4
SCHEMBL16205967 0.92 SLC22A12 (0.42) SLC22A12FFAR1KMT2ANR1H4PTGER4
SCHEMBL16206003 0.91 CHRNB1 (0.41) SLC22A12
SCHEMBL16205936 0.90 GRM5 (0.38) SLC22A12MEN1KMT2APOLBRXFP1
SCHEMBL17614547 0.90 PTGER4 (0.40) SLC22A12FFAR1TSHRPOLBNR1H4
SCHEMBL17614551 0.90 MRGPRX4 (0.43) SLC22A12FFAR1NR1H4PTGER4MAOB
SCHEMBL17614546 0.89 SLC22A12 (0.39) SLC22A12FFAR1KMT2ANR1H4PTGER4
SCHEMBL16683824 0.89 NR4A2 (0.44) MEN1KMT2ASMPD1MAOBRXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2990404-B1 TETRAZOLINONE COMPOUND AND USE OF SAME SUMITOMO CHEMICAL CO (JP) 2020-05-27 EP disclosed
US-9867372-B2 Tetrazolinone compound and use of same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2018-01-16 US disclosed
US-9867372-B2 Tetrazolinone compound and use of same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2018-01-16 US disclosed
US-20160081339-A1 TETRAZOLINONE COMPOUND AND USE OF SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-03-24 US disclosed
US-20160081339-A1 TETRAZOLINONE COMPOUND AND USE OF SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-03-24 US disclosed
WO-2014175465-A1 TETRAZOLINONE COMPOUND AND USE OF SAME 住友化学株式会社 (JP) 2014-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160081339-A1 TETRAZOLINONE COMPOUND AND USE OF SAME MT-CO1, SOD1, MT-CO2 SLC22A12 3344/4885EGLN1 342/4885FFAR1 1688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.